SH3BP2

Across TCGA pan-cancer cohorts, SH3BP2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SH3BP2 data layer compared with 26 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher SH3BP2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated SH3BP2 expression acts as an unfavorable survival marker, although some lineages such as HNSC and CCRCC show a favorable association.

HNSC, LUAD, and PDAC are the cancer types where SH3BP2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Quartile	All	0.923	0.609	.004	45	view →
LUAD	OS	Median	III,IV	0.329	0.828	.002	19	view →
PDAC	OS	Quartile	II,III,IV	0.390	0.698	.008	12	view →
CCRCC	OS	Median	III,IV	0.817	0.525	.010	5	view →
LSCC	DFS	Median	II,III,IV	0.678	0.878	.020	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SH3BP2–HNSC (OS)

Open the HNSC breakdown →